Sight Sciences reported record revenue of $24.9 million, growing 25% year over year, and raised full-year 2026 revenue guidance to $92 to $93 million while maintaining adjusted operating expense guidance of $92 to $94 million.
SGHT · Sight Sciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Sight Sciences reported nine-month revenue of $68.0 million, up 19.4%, and a net loss of $24.2 million versus $34.3 million. Cash and cash equivalents totaled $77.4 million as of September 30, 2026.
Sight Sciences reported third-quarter revenue of $24.9 million, up 25%, and raised full-year 2026 revenue guidance to $92 million to $93 million from $88 million to $92 million. Cash usage fell 74% to $2.4 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% year over year, and raised full-year 2026 revenue guidance to $92 million-$93 million. IDE and IG advanced, OMNI Ultra launched, IDE gross margin improved, and cash burn fell 74%, while operating expenses increased and early-stage IDE forecasting, market-access timing, and broader business risks remain.
- + Third-quarter revenue rose 25% to a record $24.9 million, extending the company's return to double-digit growth. new
- + Management raised full-year 2026 revenue guidance to $92 million-$93 million and increased the IDE outlook to approximately $12 million. new
- + IDE gross margin increased to 79% from 38% in the prior-year period, primarily because of higher average selling prices. new
- − Adjusted operating expenses increased 21% to $24.0 million as the company invested in growth in both segments. new
- − The timing of additional TierCare fee schedules and payer coverage decisions remains uncertain and outside the company's control. new
- − TierCare guidance reflects the difficulty of forecasting the business because it remains in the early stages of market development. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Operating Expenses non-GAAP | 43.49M | Six Months Ended June 30, 2026 | — |
| Cash usage | $5.2M | Q2 2026 | — |
| IDE patient lives added | 4.1M | Q2 2026 | — |
| Interventional Dry Eye active customers | 176 | Three Months Ended June 30, 2026 | — |
| Interventional Dry Eye lid treatment units sold | 3,091 | Three Months Ended June 30, 2026 | — |
| Interventional Glaucoma active customers | 1,214 | Three Months Ended June 30, 2026 | — |
| Total IDE patient lives with access to appropriate reimbursement | 14.5M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGHT
this stock
Sight Sciences, Inc.
|
$601.92M | +36.6% | -3.1% | — | 2.0% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 18
Sight Sciences reported nine-month revenue of $68.0 million, up 19.4%, and a net loss of $24.2 million versus $34.3 million. Cash and cash equivalents totaled $77.4 million as of September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGHT | +7.4% | +30.8% | +117.0% | +16.2% | +36.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +4.9% | +32.0% | +116.5% | +16.4% | +26.0% |